
The Central Drug Standard Control Organisation (CDSCO) has permitted Sun Pharma to manufacture and market the fixed-dose combination Silodosin JP plus Tadalafil. The firm presented its proposal and the Phase Ill CT report before the committee. Silodosin is an alpha-blocker that is used to improve urination in men with benign prostatic hyperplasia (enlarged prostate). Tadalafil is a phosphodiesterase five inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.
Like
Save
Share